Cancer drug developer CG Oncology valued at $1.75 bln in strong …

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

CouponFollow Extension

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

4 weeks from now

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

6%
OFF

UPDATE 2-Cancer Drug Developer CG Oncology Valued At $1.75 …

4 weeks from now

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

yahoo.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Nasdaq

4 weeks from now

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as demand for new …

nasdaq.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Billion In …

4 weeks from now

By Pritam Biswas (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as …

investing.com

$1.75
OFF

CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …

4 weeks from now

5 days ago · CG Oncology valued at $1.75 bln in strong market debut. CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the …

stockanalysis.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Yahoo …

4 weeks from now

CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq.

yahoo.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Billion In …

4 weeks from now

Jan 25, 2024 · (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new …

yahoo.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut

4 weeks from now

Jan 25, 2024 · CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq. ...

marketscreener.com

$1
OFF

Cancer Drug Developer CG Oncology Targets Near $1 Bln Valuation …

4 weeks from now

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. Cancer drug developer CG Oncology said on …

yahoo.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

4 weeks from now

Jan 25, 2024 · TradingView India. Cancer drug developer CG Oncology NASDAQ:CGON notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% …

tradingview.com

$1
OFF

CG Oncology Targets Near $1 Billion Valuation In US IPO - Yahoo …

4 weeks from now

Jan 18, 2024 · The company is developing a therapy for patients with bladder cancer. Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. …

yahoo.com

$180
OFF

CG Oncology Lines Up $180m IPO And A $1bn Valuation

4 weeks from now

Jan 19, 2024 · CG Oncology joins the queue of US biotech companies hoping to complete an IPO, aiming to raise $181m for its late-stage bladder cancer therapy. ... and if successful will …

pharmaphorum.com

$1
OFF

UPDATE 1-CG Oncology Targets Near $1 Bln Valuation In US IPO

4 weeks from now

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. CG Oncology is one of a handful of companies …

yahoo.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO | Reuters

4 weeks from now

Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. The company is developing a therapy …

reuters.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

4 weeks from now

Jan 18, 2024 · Adds details on company's business, IPO terms in paragraphs 2-6. Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation …

nasdaq.com

$306
OFF

Drug Developer CG Oncology Targets Up To $306 Mln For Upsized IPO

4 weeks from now

Jan 23, 2024 · Adds background, IPO detail in paragraphs 2-6. Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. …

nasdaq.com

$306
OFF

UPDATE 2-Drug Developer CG Oncology Targets Up To $306 Mln …

4 weeks from now

Jan 23, 2024 · Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its upsized initial public offering in New York, underscoring the resurgent …

yahoo.com

FAQs about Cancer drug developer CG Oncology valued at $1.75 bln in strong … Coupon?

How much is CG oncology worth?

Jan 25 (Reuters) - Cancer drug developer CG Oncology (CGON.O) notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up pace. ...

Will CG oncology raise $306 million?

Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. initial public offering, higher than it had previously expected. ...

Where will CG Oncology list its shares?

The company has applied to list its shares on the Nasdaq Global Market under the ticker CGON. CG Oncology did not say how many shares it planned to offer or give an estimated price range. The company plans to use proceeds primarily for supporting operations. ...

How many shares will CG Oncology offer in its IPO?

CG Oncology did not say how many shares it planned to offer in its IPO. The company plans to use proceeds primarily for supporting operations. The company has applied to list its shares on the Nasdaq Global Market under the ticker CGON. ...

Who are CG oncology's biggest shareholders?

Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. CG Oncology is one of a handful of companies from the healthcare sector looking to list in the coming months, as a market rally on hopes of a soft landing for the economy eases pressure on startups looking to go public. ...

What is CG Oncology's potential therapeutic for?

The Irvine, Calif.-based biopharmaceutical company is developing a potential therapeutic for bladder-cancer patients who are unresponsive to immunotherapy Bacillus Calmette-Guerin treatment. Bladder-cancer treatment developer CG Oncology filed for an initial public offering with the Securities and Exchange Commission. ...